Researchers identify new drug class with potential in BRCA-mutated tumours
POLQ inhibitors could be used to kill PARP inhibitor-resistant cancer cells
Read More
Tag: Artios
Artios, Novartis form cancer therapies collaboration
The deal could be worth as much as $1.3 billion to Artios
Read More
Artios in-licenses experimental cancer drug
Cambridge, UK-based Artios Pharma has exercised an option to in-license the first nuclease drug development programme from its research alliance with Masaryk University in the Czech Republic.
Read More
Imperial Innovations streams £5.1m into new biotech Artios
Imperial Innovations is streaming £5.1 million into newborn biotech Artios Pharma, giving the firm a 14.9 percent stake in its business.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
